Articles On Opthea (ASX:OPT)

In afternoon trade the S&P/ASX 200 index has given back a good portion of its morning gains but remains on course to finish the day in positive territory. At the time of writing the index is up 0.15% to 6,488.1 points. Four shares that...

Opthea (ASX: OPT) shares have more than doubled this morning after announcing its Phase IIb clinical trial was a success. The 366-patient study tested its OPT-302 drug, which battles wet (neovascular) age-related macular degeneration (AMD)...

Biopharmaceutical company Opthea (ASX: OPT) has taken an affirmative step towards commercialising its OPT-302 combination therapy after publishing positive phase 2b clinical trial results that included 366 patients. With the results publish...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The Althea Group Holdings Ltd (ASX: AGH) share price could be on a high on Wednesday following the release of a very positive patient update by the cannabis company this morning. What was announced? This morning Althea provided an update i...

The Opthea Ltd (ASX: OPT) share price will return from its trading halt this morning and could surge higher following the release of a very positive announcement by the developer of novel biologic therapies for the treatment of eye disease...

On Stockhead today – mining lithium from seawater, our monthly dairy stocks update, and why Hot Copper’s not leading the stocks chat space anymore. But first here’s what you need to know. The day ahead It’s the final day of Diggers and Deal...

Opthea (ASX:OPT) is scheduled to update investors tomorrow on the ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD).

30 Jul 2019 - Ophthalmic disease therapies company, Opthea (ASX:OPT) has today announced that the European Patent Office (EPO) intends to grant a patent covering one of Opthea's OP…

Opthea (ASX:OPT) has announced that the timing of the primary analysis from its ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) will be brought forward by one quarter.

Companies and institutions that provide medical assistance and services, manufactures of medical equipment, engage in clinical trials and development of drugs, are part of the healthcare sector. The Australian government makes significant c...